ArticleFEBS open bio2026
KDAC6 alters cell morphology and motility through positive and negative modulation of F-actin distribution.
Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Lysine deacetylase 6 (KDAC6 or HDAC6) has been associated with cell motility and deacetylation of cytoskeleton-related proteins. KDAC6 is the only human KDAC having three identified major domains, including two catalytic domains (CD). Defining the roles of KDAC6 in cell motility has been constrained by limited understanding of domain-specific contributions. Live and fixed cell imaging was used to characterize the effects of KDAC6 on F-actin distribution, cell morphology, and cell motility of genetically modified HT1080 cells containing KDAC6 with an inactivated CD or knockout. CD1 inactivation resulted in cells that migrated faster and had more concentrated cortical F-actin at the leading edge. Conversely, inactivation of CD2 resulted in slower migration, depleted cortical F-actin, more stress fibers with poor alignment, and larger, flatter cells. Loss of both CD1 and CD2 activity in the knockout cell line resulted in phenotypes that were most similar to wild-type cells. Hyperacetylation of α-tubulin alone was insufficient to explain the observed phenotypes of the cell line with inactive CD2, as the knockout cell line had similar hyperacetylation but lacked most of the phenotypic changes. Altered gene expression implicated actin-associated proteins as mediators of phenotypic effects. Although the cell lines exhibited variation in localization of putative KDAC6 targets cortactin and HSP90, these variations did not correlate with the observed phenotypes. Inactivation of CD2 resulted in more focal adhesions formed throughout cells, correlating with more stress fibers and reduced motility. Collectively, these results establish that each CD of KDAC6 has a distinctive and opposing role in F-actin regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.